Literature DB >> 28053233

Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling.

Andrew M Kidger1, Linda K Rushworth1, Julia Stellzig1, Jane Davidson1, Christopher J Bryant2, Cassidy Bayley2, Edward Caddye2, Tim Rogers3, Stephen M Keyse4, Christopher J Caunt5.   

Abstract

Deregulated extracellular signal-regulated kinase (ERK) signaling drives cancer growth. Normally, ERK activity is self-limiting by the rapid inactivation of upstream kinases and delayed induction of dual-specificity MAP kinase phosphatases (MKPs/DUSPs). However, interactions between these feedback mechanisms are unclear. Here we show that, although the MKP DUSP5 both inactivates and anchors ERK in the nucleus, it paradoxically increases and prolongs cytoplasmic ERK activity. The latter effect is caused, at least in part, by the relief of ERK-mediated RAF inhibition. The importance of this spatiotemporal interaction between these distinct feedback mechanisms is illustrated by the fact that expression of oncogenic BRAFV600E, a feedback-insensitive mutant RAF kinase, reprograms DUSP5 into a cell-wide ERK inhibitor that facilitates cell proliferation and transformation. In contrast, DUSP5 deletion causes BRAFV600E-induced ERK hyperactivation and cellular senescence. Thus, feedback interactions within the ERK pathway can regulate cell proliferation and transformation, and suggest oncogene-specific roles for DUSP5 in controlling ERK signaling and cell fate.

Entities:  

Keywords:  DUSP; ERK; MAPK; MKP; signaling

Mesh:

Substances:

Year:  2017        PMID: 28053233      PMCID: PMC5255582          DOI: 10.1073/pnas.1614684114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  57 in total

1.  The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier.

Authors:  Oliver E Sturm; Richard Orton; Joan Grindlay; Marc Birtwistle; Vladislav Vyshemirsky; David Gilbert; Muffy Calder; Andrew Pitt; Boris Kholodenko; Walter Kolch
Journal:  Sci Signal       Date:  2010-12-21       Impact factor: 8.192

2.  Nuclear to cytoplasmic shuttling of ERK promotes differentiation of muscle stem/progenitor cells.

Authors:  Inbal Michailovici; Heather A Harrington; Hadar Hay Azogui; Yfat Yahalom-Ronen; Alexander Plotnikov; Saunders Ching; Michael P H Stumpf; Ophir D Klein; Rony Seger; Eldad Tzahor
Journal:  Development       Date:  2014-06-12       Impact factor: 6.868

3.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

Review 4.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

5.  Cross-talk between the p38alpha and JNK MAPK pathways mediated by MAP kinase phosphatase-1 determines cellular sensitivity to UV radiation.

Authors:  Christopher J Staples; David M Owens; Jana V Maier; Andrew C B Cato; Stephen M Keyse
Journal:  J Biol Chem       Date:  2010-06-11       Impact factor: 5.157

6.  Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cells.

Authors:  Jasminka Omerovic; Michael J Clague; Ian A Prior
Journal:  Biochem J       Date:  2010-01-27       Impact factor: 3.857

Review 7.  Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

Authors:  C J Marshall
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

8.  Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.

Authors:  Ana Herrero; Adán Pinto; Paula Colón-Bolea; Berta Casar; Mary Jones; Lorena Agudo-Ibáñez; Rebeca Vidal; Stephan P Tenbaum; Paolo Nuciforo; Elsa M Valdizán; Zoltan Horvath; Laszlo Orfi; Antonio Pineda-Lucena; Emilie Bony; Gyorgy Keri; Germán Rivas; Angel Pazos; Rafael Gozalbes; Héctor G Palmer; Adam Hurlstone; Piero Crespo
Journal:  Cancer Cell       Date:  2015-08-10       Impact factor: 31.743

9.  Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling.

Authors:  Daniel A Ritt; Daniel M Monson; Suzanne I Specht; Deborah K Morrison
Journal:  Mol Cell Biol       Date:  2009-11-23       Impact factor: 4.272

10.  Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression.

Authors:  Linda K Rushworth; Andrew M Kidger; Laurent Delavaine; Graeme Stewart; Susanne van Schelven; Jane Davidson; Christopher J Bryant; Edward Caddye; Philip East; Christopher J Caunt; Stephen M Keyse
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

View more
  26 in total

1.  Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells.

Authors:  Bryant Harbourne; Min Hee Oh; William W Lockwood; Harold Varmus; Arun M Unni; Sophia Wild; John R Ferrarone
Journal:  Elife       Date:  2018-11-26       Impact factor: 8.140

2.  GP78 Cooperates with Dual-Specificity Phosphatase 1 To Stimulate Epidermal Growth Factor Receptor-Mediated Extracellular Signal-Regulated Kinase Signaling.

Authors:  Dhong Hyo Kho; Mohammed Hafiz Uddin; Madhumita Chatterjee; Andreas Vogt; Avraham Raz; Gen Sheng Wu
Journal:  Mol Cell Biol       Date:  2019-05-14       Impact factor: 4.272

Review 3.  Dual-Specificity Phosphatases and Kidney Diseases.

Authors:  Haiyang Li; Jiachuan Xiong; Yu Du; Yinghui Huang; Jinghong Zhao
Journal:  Kidney Dis (Basel)       Date:  2021-12-01

4.  Discovery and Characterization of Halogenated Xanthene Inhibitors of DUSP5 as Potential Photodynamic Therapeutics.

Authors:  Ramani Ramchandran; Daniel S Sem; Robert D Bongard; Michael Lepley; Adam Gastonguay; Raulia R Syrlybaeva; Marat R Talipov; Rachel A Jones Lipinsky; Noah R Leigh; Jaladhi Brahmbhatt; Raman Kutty; Rajendra Rathore
Journal:  J Photochem Photobiol A Chem       Date:  2019-02-10       Impact factor: 4.291

5.  Long noncoding RNA CRNDE promotes colorectal cancer cell proliferation via epigenetically silencing DUSP5/CDKN1A expression.

Authors:  Jie Ding; Juan Li; HaiYan Wang; Yun Tian; Min Xie; XueZhi He; Hao Ji; Zhonghua Ma; Bingqing Hui; Keming Wang; Guozhong Ji
Journal:  Cell Death Dis       Date:  2017-08-10       Impact factor: 8.469

6.  Identification of key microRNAs and genes in preeclampsia by bioinformatics analysis.

Authors:  Shouling Luo; Nannan Cao; Yao Tang; Weirong Gu
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

Review 7.  ETS-targeted therapy: can it substitute for MEK inhibitors?

Authors:  Osamu Tetsu; Frank McCormick
Journal:  Clin Transl Med       Date:  2017-05-02

Review 8.  Dual-specificity MAP kinase phosphatases in health and disease.

Authors:  Ole-Morten Seternes; Andrew M Kidger; Stephen M Keyse
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-09-08       Impact factor: 4.739

9.  DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.

Authors:  Lars Tögel; Rebecca Nightingale; Rui Wu; Anderly C Chüeh; Sheren Al-Obaidi; Ian Luk; Mercedes Dávalos-Salas; Fiona Chionh; Carmel Murone; Daniel D Buchanan; Zac Chatterton; Oliver M Sieber; Diego Arango; Niall C Tebbutt; David Williams; Amardeep S Dhillon; John M Mariadason
Journal:  Sci Rep       Date:  2018-01-29       Impact factor: 4.379

10.  DUSP5 functions as a feedback regulator of TNFα-induced ERK1/2 dephosphorylation and inflammatory gene expression in adipocytes.

Authors:  Justine S Habibian; Mitra Jefic; Rushita A Bagchi; Robert H Lane; Robert A McKnight; Timothy A McKinsey; Ron F Morrison; Bradley S Ferguson
Journal:  Sci Rep       Date:  2017-10-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.